2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
9 August 2022Portfolio NewsCerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease- 9 August 2022Portfolio NewsOn heels of Parkinson’s readout, Cerevance enters Alzheimer’s discovery deal with Merck
- 17 July 2022SV NewsUK has missed chances to prepare for future pandemics, says [Kate Bingham] ex-vaccines tsar
13 July 2022Portfolio NewsFDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer
6 July 2022Portfolio NewsNitrase Therapeutics Expands Leadership Team with Accomplished Drug Discovery and Development Executives
30 June 2022Portfolio NewsRia Health Secures $18 Million Series A to Scale Online Alcohol Use Disorder Treatment- 21 June 2022Portfolio NewsQurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board
9 June 2022Portfolio NewsMemorial Hermann Health System Joins Existing Investors in Leiters, a 503B Outsourced Pharmaceutical Compounding Industry Leader
8 June 2022Portfolio NewsSV Health Investors announces acquisition of Nordic Consulting Partners by Accrete Health Partners, a strategic holding company of Bon Secours Mercy Health
31 May 2022Portfolio NewsTransine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development
26 May 2022Portfolio NewsAlchemab appoints Young T. Kwon as Chief Executive Officer
25 May 2022Portfolio NewsPrilenia Announces Publication of Data Elucidating a Mechanism for Neuroprotective Potential of Pridopidine
